Hims says Peptides+ will launch later this month

Hims & Hers Health said on its November 9, 2026, third-quarter earnings call that Peptides+, the specialty it previewed last month, will launch later this month, while BPC-157 and TB-500 remain tied to the regulatory process. The remarks add a launch window to the October 29 waitlist preview and come the same day the company reported third-quarter results (report).

The call quotes below are from a Benzinga transcript of the webcast. Benzinga notes that automated transcripts can contain errors. Hims’ own newsroom posts and the Federal Register notice are used to check the product list and the regulatory backdrop.

What Hims said it will launch this month

In prepared remarks, Chief Executive Officer Andrew Dudum said the company is “confident in launching our Peptides Plus offering later this month, which will include clinician-led treatment plans and access to regular blood testing.” He also said, “We plan to follow with TB-500 and BPC-157 manufactured and compounded in the U.S.”

Chief Financial Officer Oluyemi Okupe put a more specific first-phase list on the record: “Later this month we expect to launch the first phase of our peptide offering that includes Sermorelin, glutathione, and NAD. We plan to add BPC-157 and TB-500 when the regulatory environment permits.” Okupe added that “revenue contribution from our peptide offering is not expected to be material in the fourth quarter” and that the company would “closely monitor the regulatory landscape to inform the overall breadth of the offering.”

In a later answer to a shareholder question, Dudum said “the Peptide Plus category is going to be coming to market end of this month, which includes things like glutathione, NAD, Sermorelin, B12,” and that additional therapies “like 157 and 500” would be brought to the platform “as those become allowed from a regulatory standpoint.”

The company’s branding in the newsroom is Peptides+. The call used “Peptides Plus” and “Peptide Plus category.” A same-day newsroom post, “How We’re Building the Customer Relationship in Health,” also described Peptides+ as next, “with clinician-led treatment plans and access to regular blood testing to monitor progress,” but did not name individual products or a calendar date.

How that compares with the October 29 preview

On October 29, 2026, Dudum’s newsroom post “Expanding Safe Access to Peptides” said Hims planned to offer access to sermorelin, glutathione, B12, NAD+, and L-carnitine, “with BPC-157 and TB-500 to follow when allowable.” That post is the source for L-carnitine. It was not named on the November 9 call. The newsroom used “NAD+”; the transcript uses “NAD.”

Hims opened a waitlist with that October 29 post (report). A launch later this month is still a company plan, not a confirmation that orders have started.

Manufacturing claims

Asked how much peptide manufacturing Hims intends to bring in-house, Dudum said, “we acquired and have integrated a peptide manufacturing facility in Menlo Park.” He said that for “some of the newer peptides,” including “the raw active ingredients like TB-500 and 157,” existing “manufacturing supply chains are not really at the quality that we’d like to see.” He added, “We’ll be manufacturing the raw APIs in our facilities in Menlo Park, which I think actually positions us as really the only company in the U.S. capable of having that degree of quality oversight for these therapies.”

That “only company” line is Dudum’s characterization. It is not independently verified here.

The HHS draft, not an approval

The limitation Hims keeps citing is the unfinished federal process around 503A compounding of certain peptide bulks. On October 30, 2026, HHS published a notice of availability in the Federal Register at 91 FR 68526-68527 (FR Doc. 2026-22192, Docket No. HHS-OASH-2026-0496). The notice describes a draft “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” while the 503A bulks list is developed through rulemaking. Amino Wire’s earlier report on that notice is here.

The notice is a draft. It is framed around compounding under section 503A, not section 503B outsourcing facilities. It states that compounded drugs “are not FDA-approved,” that the draft “does not establish any rights for any person and is not binding on HHS or the public,” and that written comments may be submitted via regulations.gov on that docket until two weeks after the October 30 publication date. The notice does not print a clock time for the close of comments.

On the call, Dudum said the company is “in a comment period” and that he expected more clarity “in the next couple of weeks” and “in the next few weeks” about testing and facility standards. He also said, “I’ll butcher the actual terminology,” and described the document as a case where “the FDA has put out the proposed ruling from HHS.” The Federal Register notice itself is an HHS Office of the Secretary announcement of a draft enforcement-discretion policy, not an FDA final rule and not an approval of BPC-157, TB-500, or any other peptide drug.

What is not known

• Whether the late-November launch happens on schedule, and in which states. “Later this month” and “end of this month” are statements of plan on a November 9 call.
• The first-phase product list. Okupe named sermorelin, glutathione, and NAD. Dudum’s later answer added B12. The October 29 post also listed L-carnitine and used NAD+. The company has not published a final catalog or eligibility rules.
• When, or whether, BPC-157 and TB-500 will be offered. Hims has tied those two to the regulatory process. The HHS notice is draft enforcement discretion, not a final 503A bulks-list rule.
• The Menlo Park manufacturing claim. Dudum said Hims will make raw APIs there. This story does not independently confirm facility status, output, or that Hims is the only U.S. company with that oversight.